Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.

Abstract
BACKGROUND We studied the joint effect of baseline triglyceride and lipoprotein cholesterol levels on the incidence of cardiac end points in the trial group (n = 4,081) of the Helsinki Heart Study, a 5-year randomized coronary primary prevention trial among dyslipidemic middle-aged men. The relative risks (RR) were calculated using Cox proportional hazards models with a dummy variable technique that allows simultaneous study of subgroup combinations from the placebo and treatment groups.
METHODS AND RESULTS In the placebo group (n = 2,045), the low density lipoprotein cholesterol (LDL-C)/high density lipoprotein cholesterol (HDL-C) ratio was the best single predictor of cardiac events. This ratio in combination with the serum triglyceride level revealed a high-risk subgroup: subjects with LDL-C/HDL-C ratio greater than 5 and triglycerides greater than 2.3 mmol/l had a RR of 3.8 (95% CI, 2.2-6.6) compared with those with LDL-C/HDL-C ratio less than or equal to 5 and triglyceride concentration less than or equal to 2.3 mmol/l. In subjects with triglyceride concentration greater than 2.3 mmol/l and LDL-C/HDL-C ratio less than or equal to 5, RR was close to unity (1.1), whereas in those with triglyceride level less than or equal to 2.3 mmol/l and LDL-C/HDL-C ratio greater than 5, RR was 1.2. The high-risk group with LDL-C/HDL-C ratio greater than 5 and triglyceride level greater than 2.3 mmol/l profited most from treatment with gemfibrozil, with a 71% lower incidence of coronary heart disease events than the corresponding placebo subgroup. In all other subgroups, the reduction in CHD incidence was substantially smaller.
CONCLUSIONS Serum triglyceride concentration has prognostic value, both for assessing coronary heart disease risk and in predicting the effect of gemfibrozil treatment, especially when used in combination with HDL-C and LDL-C.
- Copyright © 1992 by American Heart Association
This Issue
Article Tools
- Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.V Manninen, L Tenkanen, P Koskinen, J K Huttunen, M Mänttäri, O P Heinonen and M H FrickCirculation. 1992;85:37-45, originally published January 1, 1992http://dx.doi.org/10.1161/01.CIR.85.1.37
Citation Manager Formats
Share this Article
- Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment.V Manninen, L Tenkanen, P Koskinen, J K Huttunen, M Mänttäri, O P Heinonen and M H FrickCirculation. 1992;85:37-45, originally published January 1, 1992http://dx.doi.org/10.1161/01.CIR.85.1.37
Related Articles
- No related articles found.
Cited By...
- Pharmacological Targeting of the Atherogenic Dyslipidemia Complex: The Next Frontier in CVD Prevention Beyond Lowering LDL Cholesterol
- Blood triacylglycerols: a lipidomic window on diet and disease
- Impact of obstructive sleep apnoea on insulin resistance in nonobese and obese children
- Elevated Triglyceride Level Is Independently Associated With Increased All-Cause Mortality in Patients With Established Coronary Heart Disease: Twenty-Two-Year Follow-Up of the Bezafibrate Infarction Prevention Study and Registry
- Dietary saturated fat intake and atherosclerotic vascular disease mortality in elderly women: a prospective cohort study
- Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy: Randomized, Placebo-Controlled Study (FIRST)
- Polygenic risk for hypertriglyceridemia is attenuated in Japanese men with high fitness levels
- Taking Diabetes to Heart--Deregulation of Myocardial Lipid Metabolism in Diabetic Cardiomyopathy
- The potential effect of vanadium compounds on glucose-6-phosphatase
- Association Between Fasting Blood Glucose and Carotid Intima-Media Thickness of Polycystic Ovary Syndrome Patients With Normal Glucose Tolerance
- Type 2 diabetes and cardiovascular diseases: do they share a common soil? The Asian Indian experience
- Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada
- High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention
- Personalized vascular medicine: Individualizing drug therapy
- Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care
- Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians
- Increased VLDL-Triglyceride Secretion Precedes Impaired Control of Endogenous Glucose Production in Obese, Normoglycemic Men
- Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
- Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
- The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid Trial: What we learn from subgroup analyses
- Gender differences in vascular function and insulin sensitivity in young adults
- Anacetrapib and Dalcetrapib: Two Novel Cholesteryl Ester Transfer Protein Inhibitors
- Basal and Insulin Mediated VLDL-Triglyceride Kinetics in Type 2 Diabetic Men
- Adding monounsaturated fatty acids to a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia
- Blood Rheology and the Low-Density Lipoprotein Cholesterol/High-Density Lipoprotein Cholesterol Ratio in Dyslipidaemic and Normolipidaemic Subjects
- Community Programs for the Prevention of Cardiovascular Disease: A Systematic Review
- Diabetic dyslipidemia: extending the target beyond LDL cholesterol
- Endothelial function in subjects with isolated low HDL cholesterol: role of nitric oxide and circulating progenitor cells
- Triglycerides and HDL Cholesterol: Stars or second leads in diabetes?
- Dyslipidemia and cardiovascular risk: the importance of early prevention
- Pleiotropic Action of Short-Term Metformin and Fenofibrate Treatment, Combined With Lifestyle Intervention, in Type 2 Diabetic Patients With Mixed Dyslipidemia
- Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review
- Admixture mapping of quantitative trait loci for blood lipids in African-Americans
- Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
- Prevalence of Insulin Resistance and Related Risk Factors for Cardiovascular Disease in Patients With Essential Hypertension
- Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD?
- Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease
- From individual risk factors and the metabolic syndrome to global cardiometabolic risk
- Impact of Triglyceride Levels Beyond Low-Density Lipoprotein Cholesterol After Acute Coronary Syndrome in the PROVE IT-TIMI 22 Trial
- Metabolic Complications of Childhood Obesity: Identifying and mitigating the risk
- Fasting versus Nonfasting Triglycerides and the Prediction of Cardiovascular Risk: Do We Need to Revisit the Oral Triglyceride Tolerance Test?
- The role of fenofibrate in clinical practice
- Fenofibrate Therapy Ameliorates Fasting and Postprandial Lipoproteinemia, Oxidative Stress, and the Inflammatory Response in Subjects With Hypertriglyceridemia and the Metabolic Syndrome
- Lipid-lowering effects of anti-angiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice
- Efficacy of Monascus purpureus Went rice on lowering lipid ratios in hypercholesterolemic patients
- Potentially modifiable classic risk factors and their impact on incident myocardial infarction: results from the EPIC-Potsdam study
- The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease)
- Screening Children to Identify Families at Increased Risk for Cardiovascular Disease
- Dual PPAR{alpha}/{gamma} Agonist Tesaglitazar Reduces Atherosclerosis in Insulin-Resistant and Hypercholesterolemic ApoE*3Leiden Mice
- Effects of Bezafibrate on HDL2/HDL3 Ratio in Postmenopausal Hypertriglyceridemic Women
- The metabolic syndrome: is this diagnosis necessary?
- Cardioprotective Properties of Fibrates: Which Fibrate, Which Patients, What Mechanism?
- Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action
- Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular Disease
- Low-density lipoprotein size and cardiovascular risk assessment
- Family Physician's Knowledge, Beliefs, and Self-reported Practice Patterns Regarding Hyperlipidemia: A National Research Network (NRN) Survey
- Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B in the Prediction of Coronary Heart Disease in Men
- Managing Abnormal Blood Lipids: A Collaborative Approach
- Evolving Concepts of Dyslipidemia, Atherosclerosis, and Cardiovascular Disease: The Louis F. Bishop Lecture
- The Metabolic Syndrome: Requiescat in Pace
- Adipose Tissue, Inflammation, and Cardiovascular Disease
- Obesity, Risk Factors, and Predicting Cardiovascular Events
- Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease
- Review: Defining the role of statins in diabetes
- Prevention and Treatment of the Metabolic Syndrome
- The metabolic syndrome: one step forward, two steps back
- Lipids and Lipoproteins in Patients With Type 2 Diabetes
- Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of Torcetrapib
- Aspects of Blood Pressure, Lipid, and Glycemic Treatment
- One-Year Glycemic Control With a Sulfonylurea Plus Pioglitazone Versus a Sulfonylurea Plus Metformin in Patients With Type 2 Diabetes
- Influence of low high-density lipoprotein cholesterol on left ventricular hypertrophy and diastolic function in essential hypertension
- Dietary and antismoking advice and ischemic heart disease mortality in men with normal or high fasting triacylglycerol concentrations: a 23-y follow-up study
- Using waist circumference as a screening tool to identify colombian subjects at cardiovascular risk
- Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group
- Statins enhance postischemic hyperemia in the skin circulation of hypercholesterolemic patients: A monitoring test of endothelial dysfunction for clinical practice?
- Association of genetic variants in the HDL receptor, SR-B1, with abnormal lipids in women with coronary artery disease
- Raising high-density lipoprotein cholesterol: where are we now?
- When and how to measure lipids and their role in CHD risk prediction
- The Metabolic Syndrome: Targeting Dyslipidaemia to Reduce Coronary Risk
- High-Density Lipoproteins Protect Isolated Rat Hearts From Ischemia-Reperfusion Injury by Reducing Cardiac Tumor Necrosis Factor-{alpha} Content and Enhancing Prostaglandin Release
- Metabolic origins and clinical significance of LDL heterogeneity
- Abnormal low-density lipoprotein subfraction profile in patients with untreated hypertension
- Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S
- Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity
- PPAR{alpha} Ligands and Clinical Trials: Cardiovascular Risk Reduction with Fibrates
- Do Total and High Density Lipoprotein Cholesterol and Triglycerides Act Independently in the Prediction of Ischemic Heart Disease?: Ten-Year Follow-Up of Caerphilly and Speedwell Cohorts
- Statin--Fibrate Combination Therapy
- Effects of a high-dose concentrate of n-3 fatty acids or corn oil introduced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol
- Common Genetic Variation in ABCA1 Is Associated With Altered Lipoprotein Levels and a Modified Risk for Coronary Artery Disease
- Serum Triglycerides and Risk of Coronary Heart Disease among Japanese Men and Women
- The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia
- High Density Lipoproteins and Arteriosclerosis : Role of Cholesterol Efflux and Reverse Cholesterol Transport
- Preliminary Guidelines for the Evaluation and Management of Dyslipidemia in Adults Infected with Human Immunodeficiency Virus and Receiving Antiretroviral Therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group
This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.








